Market Cap 28.55B
Revenue (ttm) 4.34B
Net Income (ttm) 850.00M
EPS (ttm) N/A
PE Ratio 36.56
Forward PE 35.27
Profit Margin 19.57%
Debt to Equity Ratio 0.56
Volume 2,941,700
Avg Vol 1,897,728
Day's Range N/A - N/A
Shares Out 151.30M
Stochastic %K 97%
Beta 1.47
Analysts Sell
Price Target $155.55

Company Profile

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other g...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 858 202 4500
Fax: 858 202 4766
Address:
5200 Illumina Way, San Diego, United States
M_Chromatic
M_Chromatic Jul. 2 at 4:10 PM
$ILMN Weekly chart with volume profile. Right up against the volume shelf. Let's see if Illumina will work through any potential sell orders that might be here. If so, I don't see a lot of overhead supply above 204.
0 · Reply
Johnny_Lever
Johnny_Lever Jul. 2 at 12:53 AM
$ILMN Up 16% since breaking through that inverse H&S neckline. The hourly chart showing the back-test and support at neckline. Now moving higher.
0 · Reply
Clargy
Clargy Jul. 1 at 8:26 PM
$ILMN So many biotech/genomic names acting extremely constructive. Healthiest looking industry by far.
0 · Reply
WAJeff
WAJeff Jul. 1 at 7:56 PM
$ILMN $184.75 52 week high
0 · Reply
macapower
macapower Jul. 1 at 6:58 PM
$PACB $ILMN Strategic Notes #1 Could SPRQ-Nx change Illumina’s strategic incentives regarding PACB Most ask: “Would partnering strengthen PacBio too much?” I think the more important question is: Would an acquired PACB strengthen one of Illumina’s competitors more than a strengthened independent PACB operating within a mutually beneficial partnership? Illumina previously tried to acquire PacBio because it viewed HiFi as strategically important. If Spark materially improves the economics and scalability of HiFi, waiting could increases PACB’s bargaining power while also increasing the chance that another major industry player becomes interested. Viewed this way, a partnership could represent strategic risk management rather than simply accelerating PacBio’s growth. Strategic hypothesis only—not a prediction. Disclosure: My analysis. ChatGPT assisted with editing. Not investment advice. Question: Which assumption is weakest?
1 · Reply
tarzzanman
tarzzanman Jun. 30 at 8:25 PM
$ILMN Let me see that 200$+
1 · Reply
Sunnytrading90
Sunnytrading90 Jun. 30 at 1:08 PM
$ILMN monster
0 · Reply
JFDI
JFDI Jun. 30 at 12:57 PM
$ILMN breaking out
0 · Reply
UpgradeDowngrade
UpgradeDowngrade Jun. 30 at 2:27 AM
$ILMN Bernstein has altered their rating of "Mkt Perform" and target of "$185" see consensus outlook
0 · Reply
G101SPM
G101SPM Jun. 26 at 2:22 PM
#INSIDERS $BZUN Chief Strategy Officer bought 29,000 American Depositary Shares worth approximately $83K (transaction date 6)./24 PGY Chief Executive Officer bought 16,230 Class A Ordinary Shares at $15.409 - $15.44WORTH approximately $250K (transaction date 6/24). $PSEC Chief Executive Officer / 10% owner bought 1,067,648 shares worth approximately $2.4 mln (transaction date 6/23). $ILMN Chief Legal Officer sold 615 shares at $180.00 worth approximately $111K (transaction date 6/25).
0 · Reply
Latest News on ILMN
Illumina price target raised to $200 from $180 at Guggenheim

2026-06-29T11:06:22.000Z - 5 days ago

Illumina price target raised to $200 from $180 at Guggenheim


Illumina resumed with a Market Perform at Bernstein

2026-06-26T10:30:23.000Z - 8 days ago

Illumina resumed with a Market Perform at Bernstein


Illumina price target raised to $145 from $122 at Barclays

2026-06-24T08:55:36.000Z - 10 days ago

Illumina price target raised to $145 from $122 at Barclays


The Healthcare M&A Wave

Jun 17, 2026, 12:30 PM EDT - 17 days ago

The Healthcare M&A Wave

ABT ALNY AMGN AMRX ANTX AZN BDX


Illumina upgraded to Overweight from Neutral at JPMorgan

2026-06-10T09:35:08.000Z - 24 days ago

Illumina upgraded to Overweight from Neutral at JPMorgan


Illumina (ILMN): Bullish Structure Builds After Breakout

Jun 9, 2026, 5:10 PM EDT - 25 days ago

Illumina (ILMN): Bullish Structure Builds After Breakout


Illumina price target raised to $180 from $170 at Guggenheim

2026-06-01T11:50:48.000Z - 4 weeks ago

Illumina price target raised to $180 from $170 at Guggenheim


Illumina announces new complete solution for MRD research

2026-05-28T14:32:27.000Z - 5 weeks ago

Illumina announces new complete solution for MRD research


Illumina appoints David King to board of directors

2026-05-21T20:22:02.000Z - 6 weeks ago

Illumina appoints David King to board of directors

LH


David P. King elected to Illumina's Board of Directors

May 21, 2026, 4:15 PM EDT - 6 weeks ago

David P. King elected to Illumina's Board of Directors


Illumina Transcript: AGM 2026

May 21, 2026, 1:00 PM EDT - 6 weeks ago

Illumina Transcript: AGM 2026


Illumina resumed with an Outperform at RBC Capital

2026-05-14T20:48:28.000Z - 7 weeks ago

Illumina resumed with an Outperform at RBC Capital


Illumina upgraded to Outperform from Neutral at Daiwa

2026-05-14T09:12:18.000Z - 7 weeks ago

Illumina upgraded to Outperform from Neutral at Daiwa


Illumina price target raised to $95 from $80 at Citi

2026-05-04T11:01:15.000Z - 2 months ago

Illumina price target raised to $95 from $80 at Citi


Illumina price target raised to $125 from $120 at JPMorgan

2026-05-01T13:06:15.000Z - 2 months ago

Illumina price target raised to $125 from $120 at JPMorgan


Illumina price target raised to $155 from $150 at Evercore ISI

2026-05-01T12:18:53.000Z - 2 months ago

Illumina price target raised to $155 from $150 at Evercore ISI


Illumina Earnings Call Transcript: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 2 months ago

Illumina Earnings Call Transcript: Q1 2026


Illumina Earnings release: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 2 months ago

Illumina Earnings release: Q1 2026


Illumina Slides: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 2 months ago

Illumina Slides: Q1 2026


Illumina Quarterly report: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 2 months ago

Illumina Quarterly report: Q1 2026


Illumina Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 3 months ago

Illumina Proxy statement: Proxy filing


Illumina Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 3 months ago

Illumina Proxy statement: Proxy filing


Illumina Announces Changes to Board of Directors

Apr 2, 2026, 9:07 AM EDT - 3 months ago

Illumina Announces Changes to Board of Directors


Illumina To Webcast Upcoming Investor Conference

Feb 17, 2026, 3:10 PM EST - 4 months ago

Illumina To Webcast Upcoming Investor Conference


Illumina Earnings Call Transcript: Q4 2025

Feb 5, 2026, 4:30 PM EST - 5 months ago

Illumina Earnings Call Transcript: Q4 2025


Illumina Annual report: Q4 2025

Feb 5, 2026, 4:30 PM EST - 5 months ago

Illumina Annual report: Q4 2025


Illumina Earnings release: Q4 2025

Feb 5, 2026, 4:30 PM EST - 5 months ago

Illumina Earnings release: Q4 2025


Illumina Slides: Q4 2025

Feb 5, 2026, 4:30 PM EST - 5 months ago

Illumina Slides: Q4 2025


Illumina completes acquisition of SomaLogic

Jan 30, 2026, 9:05 AM EST - 5 months ago

Illumina completes acquisition of SomaLogic


Illumina Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 10:30 AM EST - 6 months ago

Illumina Transcript: 44th Annual J.P. Morgan Healthcare Conference


Illumina Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 10:30 AM EST - 6 months ago

Illumina Slides: 44th Annual J.P. Morgan Healthcare Conference


Illumina unveils dataset to speed up AI-powered drug discovery

Jan 13, 2026, 9:18 AM EST - 6 months ago

Illumina unveils dataset to speed up AI-powered drug discovery


Illumina Appoints Dr. Eric Green as Chief Medical Officer

Jan 8, 2026, 4:30 PM EST - 6 months ago

Illumina Appoints Dr. Eric Green as Chief Medical Officer


Illumina Transcript: Wolfe Research Healthcare Conference 2025

Nov 19, 2025, 9:20 AM EST - 8 months ago

Illumina Transcript: Wolfe Research Healthcare Conference 2025


Illumina Earnings Call Transcript: Q3 2025

Oct 30, 2025, 4:30 PM EDT - 8 months ago

Illumina Earnings Call Transcript: Q3 2025


Illumina Quarterly report: Q3 2025

Oct 30, 2025, 4:30 PM EDT - 8 months ago

Illumina Quarterly report: Q3 2025


Illumina Earnings release: Q3 2025

Oct 30, 2025, 4:30 PM EDT - 8 months ago

Illumina Earnings release: Q3 2025


Illumina Slides: Q3 2025

Oct 30, 2025, 4:30 PM EDT - 8 months ago

Illumina Slides: Q3 2025


ILMN Stock vs. IQV Stock

Sep 26, 2025, 9:40 AM EDT - 10 months ago

ILMN Stock vs. IQV Stock

IQV


M_Chromatic
M_Chromatic Jul. 2 at 4:10 PM
$ILMN Weekly chart with volume profile. Right up against the volume shelf. Let's see if Illumina will work through any potential sell orders that might be here. If so, I don't see a lot of overhead supply above 204.
0 · Reply
Johnny_Lever
Johnny_Lever Jul. 2 at 12:53 AM
$ILMN Up 16% since breaking through that inverse H&S neckline. The hourly chart showing the back-test and support at neckline. Now moving higher.
0 · Reply
Clargy
Clargy Jul. 1 at 8:26 PM
$ILMN So many biotech/genomic names acting extremely constructive. Healthiest looking industry by far.
0 · Reply
WAJeff
WAJeff Jul. 1 at 7:56 PM
$ILMN $184.75 52 week high
0 · Reply
macapower
macapower Jul. 1 at 6:58 PM
$PACB $ILMN Strategic Notes #1 Could SPRQ-Nx change Illumina’s strategic incentives regarding PACB Most ask: “Would partnering strengthen PacBio too much?” I think the more important question is: Would an acquired PACB strengthen one of Illumina’s competitors more than a strengthened independent PACB operating within a mutually beneficial partnership? Illumina previously tried to acquire PacBio because it viewed HiFi as strategically important. If Spark materially improves the economics and scalability of HiFi, waiting could increases PACB’s bargaining power while also increasing the chance that another major industry player becomes interested. Viewed this way, a partnership could represent strategic risk management rather than simply accelerating PacBio’s growth. Strategic hypothesis only—not a prediction. Disclosure: My analysis. ChatGPT assisted with editing. Not investment advice. Question: Which assumption is weakest?
1 · Reply
tarzzanman
tarzzanman Jun. 30 at 8:25 PM
$ILMN Let me see that 200$+
1 · Reply
Sunnytrading90
Sunnytrading90 Jun. 30 at 1:08 PM
$ILMN monster
0 · Reply
JFDI
JFDI Jun. 30 at 12:57 PM
$ILMN breaking out
0 · Reply
UpgradeDowngrade
UpgradeDowngrade Jun. 30 at 2:27 AM
$ILMN Bernstein has altered their rating of "Mkt Perform" and target of "$185" see consensus outlook
0 · Reply
G101SPM
G101SPM Jun. 26 at 2:22 PM
#INSIDERS $BZUN Chief Strategy Officer bought 29,000 American Depositary Shares worth approximately $83K (transaction date 6)./24 PGY Chief Executive Officer bought 16,230 Class A Ordinary Shares at $15.409 - $15.44WORTH approximately $250K (transaction date 6/24). $PSEC Chief Executive Officer / 10% owner bought 1,067,648 shares worth approximately $2.4 mln (transaction date 6/23). $ILMN Chief Legal Officer sold 615 shares at $180.00 worth approximately $111K (transaction date 6/25).
0 · Reply
egcgfiend
egcgfiend Jun. 26 at 2:05 PM
$PACB $TXG $ILMN AI + genomics = cure all disease and aging
0 · Reply
BillionerOfKing
BillionerOfKing Jun. 26 at 12:59 AM
$ILMN Current Stock Price: $177.67 Contracts to trade: $180.0 ILMN Jul 17 2026 Call Entry: $6.30 Exit: $8.44 ROI: 34% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
tarzzanman
tarzzanman Jun. 25 at 8:19 PM
$ILMN Ready for 200$
0 · Reply
WAJeff
WAJeff Jun. 25 at 6:16 PM
$ILMN I’m way late but added here
2 · Reply
M_Chromatic
M_Chromatic Jun. 25 at 4:10 PM
$ILMN Breaking above the range after consolidating on top of the swing high ⚓VWAP.
0 · Reply
Woodman7
Woodman7 Jun. 25 at 3:57 PM
$CRSP $ILMN $NVDA $PACB Buyout candidate
1 · Reply
MoneyMach
MoneyMach Jun. 25 at 3:38 PM
$PACB moving today looks bigger than just a chart bounce long-read HiFi sequencing is becoming more important for rare disease, cancer, AI biology data, and complex genome discovery. With Revio/Vega upgrades, lower genome-cost goals, and big dataset collaborations, PacBio could be one of those quiet bio-platform plays that wakes up fast if adoption accelerates. High risk, but very unique upside story. $ILMN $CRSP $NVDA
1 · Reply
MoneyMach
MoneyMach Jun. 25 at 2:30 PM
Precision medicine starts with better genomic data. That’s why $PACB, $ILMN, and $CRSP remain worth watching as the field evolves.
0 · Reply
WAJeff
WAJeff Jun. 25 at 1:08 PM
$ILMN Late to the turn here but adding today. Had a frustrating 140s entry earlier this year where it dropped all the way to 114s by mid-Feb. I was then happy to get out breakeven. But as so often happens, what you saw when you first bought eventually plays out, just later than you were hoping for.
1 · Reply
Johnny_Lever
Johnny_Lever Jun. 25 at 6:44 AM
$ILMN Back-test of neckline complete. Heading higher.
0 · Reply
SwingTraderPro1
SwingTraderPro1 Jun. 24 at 11:00 PM
$PSNL is starting to look like it’s coiling for a larger directional move after building out a clean cup-and-handle structure. Price action today was strong with a +13% finish, showing buyers are stepping in with conviction rather than just passive bounce behavior. What makes this more interesting is the sector backdrop- genomics / biotech tools space is seeing broad strength across names like $TWST, $GH, $ILMN, and $TEM, which adds a tailwind to momentum continuation. When you combine a technical base + rising relative strength + hot sector flow, breakouts tend to accelerate faster than expected once prior highs are cleared. Key watch: whether this base resolves upward with volume expansion or fades back into consolidation.
1 · Reply
DeepSeaTurtle
DeepSeaTurtle Jun. 24 at 10:43 PM
$PSNL showing early signs of a potential cup-and-handle structure forming, with today’s +13% move adding some momentum confirmation. Price action is starting to tighten after a longer base, which is usually where you want to see volume and trend participation pick up if a breakout is real. The broader genomics / biotech tools theme is also active right now, with names like $TWST $GH $ILMN $TEM moving in sync at times, which helps the sector bid. Key now is follow-through. Strong base + theme support can matter, but breakout quality depends on whether volume expands and price holds gains above resistance. Still early, but this is the type of structure worth keeping on watch.
0 · Reply